Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affects the antitumor activity of doxorubicin.

S.A.B.E. van Acker, E. Boven, K. Kuiper, D.J. van den Berg, J.A. Grimbergen, K. Kramer, A. Bast, W.J.F. van der Vijgh

Research output: Contribution to JournalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1747-1754
JournalClinical Cancer Research
Volume3
Publication statusPublished - 1997

Cite this